Treatment of diseases related to hyperactivity of the complement system
AssigneeCambridge Enterprise Limited
InventorPeter Lachmann
Life of this patent
Estimating the term…
Abstract
Rising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described.
Claims20
A method for treating Age-related Macular Degeneration (AMD) or atypical haemolytic uraemic syndrome (aHUS) in a subject in need thereof, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of an agent selected from native Factor I and a polypeptide that has at least 90% amino acid identity with native Factor I and that retains C3b-inactivating and iC3b-degradation activity, and does not comprise Factor H, to the subject, and wherein the therapeutically effective amount of the agent increases the level of C3b-inactivating and iC3b-degradation activity in the plasma of the subject to a level that exceeds a normal level of C3b-inactivating and iC3b-degradation activity, thereby treating the AMD or aHUS in the subject.
A method for treating Age-related Macular Degeneration (AMD) or atypical haemolytic uraemic syndrome (aHUS) in a subject in need thereof, which comprises administering by intravenous, intraperitoneal, intramuscular, or intradermal administration a therapeutically effective amount of an agent selected from native Factor I, and a polypeptide that has at least 90% amino acid identity with native Factor I and that retains C3b-inactivating and iC3b-degradation activity, to the subject, wherein the agent is administered in the absence of Factor H, and wherein the therapeutically effective amount of the agent increases the level of C3b-inactivating and iC3b-degradation activity in the plasma of the subject to a level that exceeds a normal level of C3b-inactivating and iC3b-degradation activity, thereby treating the AMD or aHUS in the subject.
A method for treating Age-related Macular Degeneration (AMD) or atypical haemolytic uraemic syndrome (aHUS) in a subject in need thereof, which comprises administering a therapeutically effective amount of an agent selected from native Factor I, and a polypeptide that has at least 90% amino acid identity with native Factor I and that retains C3b-inactivating and iC3b-degradation activity, to the subject, wherein the agent is administered in the absence of Factor H, and wherein the therapeutically effective amount of the agent increases the level of C3b-inactivating and iC3b-degradation activity in the subject's plasma to a level that exceeds a normal plasma level of C3b-inactivating and iC3b-degradation activity, thereby treating the AMD or aHUS in the subject.
Dependencies are inferred from the claim text.